SARS-CoV-2 RBD of Spike protein, S477N – lineage B.1.526 – NY Iota Variant

Reference:
Size

100ug, 10ug

Brand

Product type

Host Species

Description of SARS-CoV-2 RBD of Spike protein, S477N – lineage B.1.526 – NY Variant – Iota Variant

Description of SARS-CoV-2 RBD of Spike protein, S477N – lineage B.1.526 – NY Variant – Iota Variant

General information on SARS-CoV-2 RBD of Spike protein, S477N – lineage B.1.526 – NY Variant – Iota Variant

During the last quarter of 2020, investigators have witnessed the rise of several variants carrying multiple mutations with biological significance. Many of these biologically relevant mutations are focused on the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2. Residues that are responsible for binding the human receptor ACE2 or those that are bound by neutralizing antibodies are the ones suffering the most changes.
In November 2020, a new lineage of SARS-CoV-2 was detected in the state of New York (USA) by researchers from Caltech and Columbia University. The most common set of mutations found in the spike protein of the new lineage – B.1.526 – are L5F, T95I, D253G, E484K or S477N (never the two at the same time), D614G, and A701V. The relative abundance of this lineage in the NY area has reached 25% in February 2021, representing a 26-fold increase in a little over a month. Its frequency is expected to keep rising in the months to come.
Mutation E484K is shared with lineages B.1.351 (South Africa) and P.1 (Brazil) and suspected to increase SARS-CoV-2’s ability to evade the immune system by reducing the potency of class 1 antibodies that target this region. Mutation S477N has also been detected in other lineages of SARS-CoV-2, but this is the first time a lineage carrying it becomes so abundance in the circulating SARS-CoV-2 population. This mutation may be associated with an increased affinity towards the human ACE2 receptor and increased resistance to SARS-CoV-2 neutralizing antibodies.
The fact that this is the first time we are seeing a steady increase of viruses carrying the S477N mutation can be explained by its association with the D253G, adjacent to the RBD. This mutation falls into the loop of the N-terminal domain (NTD) of the spike. For this reason, it is expected to abolish an important neutralizing epitope in this region and contribute to increased immune resistance. The combination of E484K or S477N with D253G may exacerbate SARS-CoV-2 infectivity and contribute to a new surge of COVID-19 cases worldwide.
This RBD fragment contains the S477N mutation found in lineage B.1.526. For the variant carrying the E484K mutation, click here.

Product nameSARS-CoV-2 RBD of Spike protein, S477N – lineage B.1.526 – NY Iota Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
Molecular weight35kDa
BufferPBS, pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
Fragment TypeSpike protein fragment
Aliases /Synonymslineage B.1.526, New Yorker variant, Nyvariant, Iota variant
ReferencePX-COV-P058
NoteFor research use only. Not suitable for in vitro diagnostic and human use.
Product nameSARS-CoV-2 RBD of Spike protein, S477N – lineage B.1.526 – NY Iota Variant
Origin speciesSARS-COV2
Expression systemEukaryotic expression
Molecular weight35kDa
BufferPBS, pH7.5
Delivery conditionDry Ice
Storage condition4°C for short term; -20°c or -80°C for long term
BrandProteoGenix
Host speciesMammalian cells
Fragment TypeSpike protein fragment
Aliases /Synonymslineage B.1.526, New Yorker variant, Nyvariant, Iota variant
ReferencePX-COV-P058
NoteFor research use only. Not suitable for in vitro diagnostic and human use.

Reviews

There are no reviews yet.

Be the first to review “SARS-CoV-2 RBD of Spike protein, S477N – lineage B.1.526 – NY Iota Variant”

Your email address will not be published.

Clear
OK

Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

Contact us to order

+33 (0)3 90 20 54 70

Write us

Categories: